Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asparaginase erythrocyte encapsulated - ERYtech Pharma

Drug Profile

Asparaginase erythrocyte encapsulated - ERYtech Pharma

Alternative Names: ERY-001; ERY-ASP; ERYASP; Eryaspase; Erythrocyte-encapsulated L-asparaginase-ERYtech-Pharma; GRASPA; L-asparaginase loaded erythrocytes-ERYtech-Pharma

Latest Information Update: 21 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ERYtech Pharma
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Acute myeloid leukaemia
  • Preclinical Breast cancer; Non-Hodgkin's lymphoma; Solid tumours
  • Preregistration Submission Withdrawal Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 18 Jan 2019 ERYTECH plans to initiate enrolment in the TRYbeCA-1 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in the US in the first quarter of 2019
  • 06 Nov 2018 Phase-III clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Finland, Austria, Denmark (IV) (EudraCT:2018-000572-15)
  • 17 Sep 2018 ERYtech Pharma plans a phase II/III trial for Breast cancer (Combination therapy, Metastatic disease, Locally recurrent) in December 2018 (NCT03674242)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top